Visiogen forms European subsidiary, releases accommodating IOL

March 2, 2009
Ophthalmology Times Staff Reports

During the winter meeting of the European Society of Cataract and Refractive Surgeons, held in early February here, Visiogen Inc. announced the formation of its European subsidiary, Visiogen Europe.

Rome

-During the winter meeting of the European Society of Cataract and Refractive Surgeons, held in early February here, Visiogen Inc. announced the formation of its European subsidiary, Visiogen Europe. Visiogen also announced that it will begin the controlled commercial release of its proprietary accommodating IOL (Synchrony) in Europe.

Visiogen was founded in Irvine, CA, in 2001. More than 1,000 of the accommodating lenses have been implanted in clinical trials.

During this recent ESCRS meeting, results from clinical research on the Synchrony dual optic accommodating IOL were featured in seven presentations and two posters. These included the initial results from new randomized, controlled European trials that compared the lens with an aspheric lens (AcrySof ReSTOR Aspheric, Alcon Laboratories) and a multifocal lens (Tecnis, Advanced Medical Optics), in which the accommodating IOL compared favorably. Results from a study from the University of Heidelberg showed objective dynamic accommodation with the accommodating lens at 5 years post-implantation.

“We are pleased with the growing interest in the [accommodating] IOL in Europe and the positive European clinical results that were presented in Rome,” said Stuart Windsor, managing director of Visiogen Europe, in a prepared statement. “The establishment of a permanent Visiogen presence in Europe is evidence of our commitment to supporting our European customers and to commercializing this exciting technology in a safe and responsible manner.”

Related Content:

News